Alder BioPharmaceuticals prices upsized IPO at $10, well below the range

Alder BioPharmaceuticals, which is developing antibodies to prevent migraine and treat rheumatoid arthritis, raised $80 million by offering 8.0 million shares at $10, below its proposed $13 to $15 range. Alder BioPharmaceuticals will list on the NASDAQ under the symbol ALDR. Credit Suisse and Leerink Partners acted as joint bookrunners on the deal.